Innitius Closes €1.8 Million Round Led by Clave Capital and Nara Capital

Innitius raises capital. The Spanish startup specialized in improving diagnostics for women’s health has closed a €1.8 million funding round led by Clave Capital and Nara Capital in which most of the investors who had previously backed the company have also joined, the company announced through a statement.

Created in 2017 and headquartered in Bilbao, Innitius aims to improve the health and quality of life of pregnant women and newborns by reducing the impact of pathologies such as preterm labor, induction of labor, or cervical cancer in society.

Read more about Innitius and discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Innitius first product

Innitius’ first product, FineBirth, is aimed at diagnosing threats of preterm labor, a pathology considered to be one of the main causes of hospitalization of patients during pregnancy.

Currently, 85% of women hospitalized with symptoms of preterm labor do not deliver and are treated unnecessarily with drugs. On the other hand, almost 20% of patients who are diagnosed as false threats of preterm labor eventually return to the emergency department, giving birth prematurely during the same pregnancy.

Innitius aims to build the world’s largest cervical consistency database, which can be used to improve women’s and neonatal health

Innitius is developing a technology based on the analysis of the consistency of the cervical tissue of the pregnant patient with labor symptoms and introducing this parameter into an artificial intelligence (AI) network, which provides gynecologists and obstetricians with a diagnosis that facilitates decision-making.

The company wants to apply this method developed for obtaining consistency in other women’s health pathologies, such as induction of labor or cervical cancer. Leveraging the results of each intervention, Innitius aims to build the world’s largest cervical consistency database that can be used to improve women’s and newborn health on a global scale.

Previous capital raisings for Innitius

Innitius has already received more than five million euros of investment, both from private institutions (Mind The Gap program of the Botín Foundation, Seed Capital Bizkaia, Basque FCR, WA4Steam) and public entities (EIC Accelerator, Enisa, EIT Health, Beaz or Spri, among others).

Innitus was founded at the end of 2017 as a spin-off of the University of Granada and the Andalusian Health Service (SAS) by the hand of Rubén Molina, CEO of the company, and Francisca Molina, clinical director, together with eight founding partners who to this day continue to develop technologies based on the use of torsion waves. Subsequently, the company moved its headquarters to Bilbao as part of the Seed Capital Bizkaia program.

__

(Featured image by StockSnap via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.